Does low-dose transdermal estradiol induce breast density and heterogeneity changes comparable to those of raloxifene?
Low-dose transdermal estradiol and raloxifene induced comparable changes in breast density and heterogeneity. Baseline correlations may be explained through relations to obesity. The current study does not yield evidence against the hypothesis that "neither raloxifene nor low dose transdermal estradiol treatment increases the breast cancer risk."
The concentrations of urine NGAL and IL-18 could be useful biomarkers for AKI in patients after cardiac surgery, especially after correction for urine creatinine.